Skip to content Skip to footer
Subscribe Now
NEWS

Polpharma Partners with Tuteur to Commercialize a Biosimilar Candidate Across LATAM for Autoimmune Diseases

Shots: Polpharma Biologics has entered into a licensing agreement with Tuteur to commercialize a biosimilar candidate for autoimmune diseases across Latin America, excl. Brazil As per the deal, Tuteur will handle commercialization, marketing, & distribution in the licensed territories, while Polpharma will be responsible for the development & manufacturing of the biosimilar candidate The biosimilar…
May 22, 2026

Read more

Merck
NEWS

Merck Reports the P-III (TroFuse-005) Trial Data on Sacituzumab Tirumotecan for Advanced or Recurrent Endometrial Cancer

Shots: Merck has reported global P-III (TroFuse-005) trial data assessing sac-TMT (4 mg/kg, Q2W) vs doxorubicin/paclitaxel in 776 pts with endometrial carcinoma & carcinosarcoma who have received prior Pt-based CT & anti-PD-1/anti-PD-L1 immunotherapy either together or separately Trial met its 1EP of improved OS & PFS in the above pts, plus it also reached its key…
May 22, 2026

Read more

NEWS

Medtronic Plans to Acquire SPR Therapeutics, Strengthening its Pain Portfolio

Shots: Medtronic has announced its intent to acquire SPR Therapeutics for an upfront payment of ~$650M, aiming to expand its neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) tech for chronic pain management Acquisition will add SPR’s FDA-cleared SPRINT PNS System to Medtronic’s pain management portfolio, which showed over 71% pts experienced significant pain relief…
May 21, 2026

Read more

Reflow Medical
NEWS

Reflow Medical Reports DEEPER CORONARY Study Results on Spur Elute Stent System for Coronary In-Stent Restenosis (ISR)

Shots: Reflow Medical has reported the DEEPER CORONARY study results evaluating the short-term safety of the coronary Spur Elute Sirolimus-Eluting Retrievable Stent System for coronary ISR at EuroPCR 2026 6mos. results showed 100% freedom from MACE & all-cause mortality in nine treated pts, while all patients demonstrated improved CCS angina class with a median improvement of…
May 21, 2026

Read more

NEWS

Eli Lilly Acquires Engage Biologics for ~$202M

Shots: Eli Lilly has acquired Engage Biologics, combining Engage’s Tethosome platform with Lilly’s genetic medicines capabilities & portfolio As per the deal, Eli Lilly acquired Engage for ~$202M in cash, incl. an upfront payment and subsequent development milestones payments The Tethosome platform is a non-viral DNA delivery system that combines engineered DNA payloads, lipid nanoparticles,…
May 21, 2026

Read more

NEWS

Incyte Expands Partnership with Genesis Molecular AI to Advance AI-Driven Drug Discovery

Shots: Incyte and Genesis have expanded their collaboration to accelerate the discovery of novel molecules for Incyte-selected targets by deploying Genesis’ GEMS molecular AI platform across a broader range of challenging targets in Incyte’s portfolio Incyte will provide experimental data to enhance GEMS’ capabilities, plus the companies will add ≥5 new targets, with options for…
May 21, 2026

Read more

NEWS

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Shots: QIAGEN to integrate its Digital Insights bioinformatics business with NVIDIA accelerated computing & the NVIDIA BioNeMo platform to strengthen AI applications in drug discovery Partnership leverages graph-based AI that apply retrieval & reasoning techniques across biomedical knowledge graphs to help researchers analyze complex biological data & validate AI-generated insights, supporting practical applications across the…
May 20, 2026

Read more

Load more